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Introduction: Patients with rheumatoid arthritis (RA) are 30–60% more likely to develop car-
diovascular disease (CV) than the general population. Metabolic syndrome (MS), deﬁned by
a  number of cardiovascular risk factors, confers a greater risk of CVdisease and diabetes.
The association of MS with RA is not yet fully understood and its prevalence varies from 19
to  63% across studies.
Objectives: To assess the prevalence of MS in a population of RA patients followed in a hos-
pital in Northeastern Brazil and analyze associations of demographic and clinical factors
with  MS.
Methods: Outpatients with RA were evaluated in a cross-sectional study regarding demo-
graphic, clinical, laboratory and anthropometric data. The criteria for deﬁning MS were those
adopted by NCEPIII (2005) and IDF (2006).
Results: 110 patients with RA were studied; 97.3% were female, with a mean age of 55.5
years (SD = 12.9) and duration of illness of 11.2 years (SD = 7.3). The MS prevalence from
NCEPIII (2005) and IDF (2005) were, respectively, 50% and 53.4%. Advanced age (57.9 ± 11.9
versus 52.9 ± 13.5; p = 0.04) and smoking load >20 packs/year (29% versus 9%, p = 0.008) were
associated with MS. The major components of the metabolic syndrome were abdominal
obesity (98.1%), hypertension (80%) and low HDL cholesterol (72.2%).
Conclusions: RA patients in a tertiary center in Northeastern Brazil showed high prevalence
of  MS. It is worth noting that almost all patients had MS and abdominal obesity, which has
important practical implications. In addition to the components of MS, age and smokingwere associated with this syndrome.© 2015 Elsevier Editora Ltda. All rights reserved.
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Síndrome  metabólica  em  pacientes  com  diagnóstico  de  artrite  reumatoide
acompanhados  em  um  Hospital  Universitário  do  Nordeste  brasileiro
Palavras-chave:
Síndrome metabólica
Artrite reumatoide
Doenc¸as cardiovasculares
r  e  s  u  m  o
Introduc¸ão: Pacientes com artrite reumatoide (AR) têm 30 a 60% mais chances de desenvolver
doenc¸as cardiovasculares (DCV) do que a populac¸ão geral. A síndrome metabólica (SM),
deﬁnida por um conjunto de fatores de risco cardiovasculares, confere maior risco de DCV e
diabete. A associac¸ão da SM com AR ainda não está totalmente esclarecida e sua prevalência
varia de 19 a 63% entre os estudos.
Objetivos: Avaliar a prevalência de SM numa populac¸ão de pacientes com AR acompanhada
num hospital do Nordeste brasileiro e analisar associac¸ões de fatores demográﬁcos e clínicos
com  SM.
Métodos: Pacientes ambulatoriais com AR foram transversalmente avaliados com relac¸ão a
dados demográﬁcos, clínicos, laboratoriais e antropométricos. Os critérios para deﬁnir SM
foram os adotados pelo NCEPIII (2005) e IDF (2006).
Resultados: Foram estudados 110 pacientes com AR, 97,3% mulheres com média de 55,5 anos
(DP = 12,9) e durac¸ão da doenc¸a de 11,2 anos (DP = 7,3). As prevalências de SM do NCEPIII
(2005) e IDF (2005) foram, respectivamente, 50% e 53,4%. Idade avanc¸ada (57,9 ± 11,9 ver-
sus 52,9 ± 13,5; p = 0,04) e carga tabágica > 20 mac¸os ano (29% versus 9%; p = 0,008) estiveram
associadas com SM. Os principais componentes da SM foram obesidade abdominal (98,1%),
hipertensão arterial (80%) e HDL baixo (72,2%).
Conclusões: Pacientes com AR de um servic¸o terciário do Nordeste brasileiro apresentaram
alta prevalência de SM. Chama atenc¸ão a quase totalidade dos pacientes com SM e obesidade
abdominal, o que traz implicac¸ões práticas importantes. Além dos componentes de SM,
idade e tabagismo se mostrarem associados com SM.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Rheumatoid arthritis (RA) is a systemic inﬂammatory, autoim-
mune, chronic disease which mainly affects peripheral joints.
Recent epidemiological studies have suggested that RA is
an independent risk factor for cardiovascular (CV) diseases,
and RA patients are 30–60% more  likely to develop (CV) dis-
eases, that are characterized as the most important cause
of morbidity and mortality in patients with RA.1,2 The
most likely explanation for this is the process of endothe-
lial dysfunction and accelerated atherosclerosis that occur
in these patients secondary to chronic inﬂammation and
also to a higher prevalence of traditional cardiovascular
risk factors. The presence of metabolic syndrome (MS), also
known as insulin resistance syndrome, characterized by the
combination of cardiovascular risk factors such as hyper-
tension, obesity, high blood glucose, insulin resistance (IR)
and dyslipidemia, confers a greater cardiovascular morbid-
ity than the sum of the risks associated with each individual
component.3
Its etiology remains elusive, but studies point to IR as
the main mediator in the pathophysiology of MS. Multi-
ple metabolic pathways have been proposed to connect IR
and compensatory hyperinsulinemia to other metabolic risk
factors.4,5 Although the role of MS  as a predictor of car-
diovascular risk has been hotly debated, a meta-analysis of2010 involving more  than 950,000 patients concluded that MS
increases twice the risk of (CV) diseases and 1.5 times the over-
all mortality, as well as an increase of ﬁve times for risk of
occurrence of type 2 diabetes mellitus.6 MS  and IR have also
been associated with several other diseases, such as hepatic
steatosis, ﬁbrosis and cirrhosis,7 polycystic ovary syndrome,8
cholelithiasis,9 sleep apnea,10 chronic kidney disease,11 and
gout.12
The prevalence of MS  in patients with RA varies from 14% to
63%.13–29 Some controlled cross-sectional studies have shown
a higher prevalence in patients than in controls,16,22,25,26,28 but
other studies found no differences.14,15,20,24,27 Epidemiological
and methodological factors may justify such different results,
for instance, the characteristics of the study population, origin
of the patients, criteria used to deﬁne MS, and study design.
However, evidence of accelerated atherosclerosis in patients
with RA related to systemic inﬂammatory activity, together
with the high prevalence of traditional cardiovascular risk fac-
tors in these patients, favor the increased risk of MS  in patients
with RA.1,3,6,13–16 The approach to cardiovascular risk factors
and MS in patients with RA is so important that in 2012 the
Brazilian Society of Rheumatology proposed a consensus on
the management of comorbidities in patients with RA, includ-
ing an early identiﬁcation and appropriate treatment of MS,
besides other cardiovascular risk factors in all patients diag-
nosed with RA.30
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The main aim of this study was to determine the preva-
ence of MS  in a population of RA patients followed in a
niversity hospital in Northeastern Brazil, and to analyze
ssociations of demographic and clinical factors with the pres-
nce of MS.
atients  and  methods
atients diagnosed with RA according to the 1988 ACR
riteria31 and followed at the Rheumatology Center outpatient
linic, Hospital Universitário Walter Cantídio, Universidade
ederal do Ceará, were sequentially invited to participate in
his study. Patients with other autoimmune diseases, except
econdary Sjogren’s syndrome, were excluded. The study
egan in January 2013 and ended in December 2013 and the
ata collection was made with a cross-sectional design in
he same period. A total of 110 patients was studied. Demo-
raphic (gender, age, race, education level) and clinical data
elated to RA (disease duration since diagnosis, the presence
f extra-articular manifestations, rheumatoid factor, cyclic
itrullinated peptide antibody [anti-CCP], medications used,
one erosions) and the presence of cardiovascular risk factors
hypertension, diabetes mellitus, dyslipidemia, heart disease,
moking) were collected from clinical records. Given that data
n smoking are often not recorded properly in the clinical
ecords, information about smoking was directly asked for the
atient at the assessment day: never smoked, smoked in the
ast, currently smoking, number of cigarettes/day and smok-
ng time. The patient was considered as a smoker if he/she
ad smoked or still was smoking for at least 6 months any
umber of cigarettes. Pack-years of smoking was calculated as
he average number of cigarettes per day multiplied by years
s a smoker, divided by 20. A history of >20 packs/year was
onsidered as heavy smoking.32 Information about dose and
uration of prednisone use also were taken from the records
nd categorized as follows: no/very low exposure: daily use
f prednisone <7.5 mg  during <3 months; low exposure: daily
se of prednisone <7.5 mg  during >6 months; medium expo-
ure: daily use of prednisone ≥7, 5–30 mg  up for >6 months.
atients without any regular physical activity, or who per-
ormed sporadic physical activity (<150 min  of activity/week),
ere classiﬁed as having a sedentary lifestyle.
During the physical examination, the number of swollen
nd tender joints was determined (28 joints) and patients were
valuated for the presence of joint deformities (reversible or
rreversible). Measurements of blood pressure, weight, height
nd waist circumference were determined in the assessment
ay. Waist circumference was measured in centimeters with
 tape at the midpoint between the lower part of the last
ib and the iliac crest. Body Mass Index (BMI) was calculated
sing the formula weight over height squared. Disease activ-
ty was measured by the instrument Disease Activity Score 28
DAS28)33 also in the study visit day, always using the last ESR
btained. Functional capacity was assessed using the Health
ssessment Questionnaire (HAQ),34 with scores from 0 to 3: meaning no loss of physical function, and 3 meaning com-
lete physical disability. Recent laboratory data (blood count,
rythrocyte sedimentation rate [ESR], C-reactive protein [CRP],
asting glucose, total cholesterol, high density lipoprotein 6;5 6(2):117–125 119
[HDL] cholesterol, triglycerides, creatinine and urea) were also
assessed.
MS  criteria
There are ﬁve deﬁnitions for MS,  all including dosages of HDL
cholesterol, triglycerides, fasting glucose and blood pressure,
and waist circumference measurement; and three of these
include criteria for IR. These deﬁnitions also differ with respect
to cutoff points in blood glucose, HDL, triglycerides and blood
pressure levels and abdominal circumference measurement.
The most widely used deﬁnitions are the Adult Treatment
Panel III of the National Cholesterol Education Program (NCEP
ATP III)35 and the International Diabetes Federation (IDF)36;
therefore, we used these two deﬁnitions updated in 2005 and
2006, respectively, to calculate only the prevalence. To com-
pare demographic and clinical factors between the group of
patients with RA and MS  versus patients with RA, but without
MS, we used the MS rate calculated by NCEP ATP III.
The NCEP ATP III (2005) criteria requires three out of
ﬁve factors to establish the diagnosis as follows: fasting
glucose ≥100 mg/dL or use of hypoglycemic agents; HDL
<40 mg/dL (men) or <50 mg/dL (women) or use of LDL lowering
drugs; triglycerides ≥150 mg/dL or use of triglyceride-lowering
medications; waist circumference ≥102 cm (men) or ≥88 cm
(women); and blood pressure ≥130/85 mmHg  or use of antihy-
pertensive drugs. The criteria to consider MS according to IDF
are: mandatory presence of abdominal circumference ≥94 cm
(men) or ≥80 cm (women) and at least two of the other four
criteria described above.
Statistical analysis was performed using Stata software
version 9.0. For descriptive analysis of general characteristics
of the sample, proportions and means ± standard deviations
(SD) were calculated. Student’s t test for independent sam-
ples was used to compare means between groups, and the
chi-squared test was applied to compare proportions. The
level of statistical signiﬁcance set at 5% (p < 0.05) was used for
all statistical tests. The study was approved by the Research
Ethics Committee of the Hospital Universitário Walter Can-
tídio (HUWC) – Universidade Federal do Ceará (Protocol. N.
086.08.11).
Results
The general characteristics of the 110 patients studied are
shown in Table 1. The mean age was 55.5 ± 12.9 years, and
most of the subjects were female (107 women and 3 men),
with low educational level (73.4%) and with the prevalence
of Caucasian/brown subjects (53.2%). The mean disease dura-
tion was 11.2 ± 7.3 years. 84% of the results for rheumatoid
factor were positive; and for anti-CCP 83.3% were positive
(10 were positive in 12 patients). X-rays of hands and feet
were obtained only from 55 patients of this sample, with 19
patients presenting joint erosions (34.5%). More  than 90% of
the patients were continuously taking oral prednisone at a
mean dose of 5.06 ± 2.20 mg/day. With respect to synthetic
disease-modifying drugs, the most used was methotrex-
ate (95.5%), followed by leﬂunomide (71.2%). Anti-TNF-alpha
agents were used by 31.8% of the patients. Disease activity
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Table 1 – Characteristics of patients with rheumatoid
arthritis followed at the Hospital Universitário Walter
Cantidio-UFC (n = 110).
Feature
Female gender, years (%) 97.3
Age (mean ± SD) 55.5  ± 12.9
Marital status (%)
Single 33.3
Married 50.9
Separated/widower 15.8
Educational level (%)
Illiterate/literate 33.0
Elementary school 40.4
High school 22.9
College 3.7
Race (%)
Caucasian 22.4
Brown 30.8
Mulatto 40.2
African American 6.6
Disease duration, years (mean ± SD) 11.2  ± 7.3
Rheumatoid factor, positive (%) 84.0
Anti-CCP (%) 83.3 (10/12)
Presence of extra-articular manifestations (%) 11.8
Irreversible deformities (%) 35.3
Bone erosions in hand and/or foot X-rays (%) 34.5 (19/55)
Current use of oral prednisone (%) 90.9
Current prednisone dose, mg/day (mean ± SD) 5.06 ± 2.23
Disease-modifying drugs used (%)
Chloroquine 59.1
Methotrexate 95.5
Sulfasalazine 15.5
Leﬂunomide 71.2
Anti-TNF (inﬂiximab, adalimumab
and/or etanercept)
31.8
Abatacept 0.9
Rituximab 1.8
Number of synthetic disease-modifying drugs
(mean ± SD)
2.4  ± 0.9
Number of biological disease-modifying drugs
(mean ± SD)
0.3  ± 0.6
Health Assessment Questionnaire (HAQ)
(mean ± SD)
0.97  ± 0.69
Disease Activity Score 28 (DAS28)
(mean ± SD)
3.97  ± 1.38
Menopause (%) 78
Metabolic syndrome prevalence (%)
NCEP ATPIII 50.0
IDF 53.4
Hypertension (%) 56.3
Triglycerides >150 mg/dL (%) 38.3
Low HDL (<50 mg/dL in men and <40 mg/dL
in women) (%)
47.2
Diabetes mellitus (%) 12.7
Abdominal obesity (%) 75.4
Smoking (%) 44.0
Smoking history >20 packs/year (%) 19.1
Sedentary lifestyle (%) 53.6
NCEP ATPIII 2005, Adult Treatment Panel III of the National
Cholesterol Education Program; IDF 2005, International Diabetes
Federation. 0 1 6;5 6(2):117–125
assessed by DAS28 at the time of evaluation was 3.97 ± 1.38,
and functional capacity assessed by HAQ was 0.97 ± 0.69.
The prevalence of MS was 50% and 53.4% by NCEP ATP
III and IDF deﬁnitions, respectively. When demographic and
clinical characteristics of patients with and without MS  were
compared (according to NCEP ATP III), only age showed sta-
tistically signiﬁcant difference, with older subjects in MS
group (57.9 versus 52.9 years; p = 0.04). Cardiovascular risk
factors (hypertension, low HDL, high triglycerides, glucose
intolerance or diabetes mellitus, abdominal adiposity, obe-
sity, smoking history >20 packs/year) were more  frequent
in patients with MS. There was no statistical difference for
inﬂammatory markers (Table 2). No relationship was found
between exposure to oral prednisone and presence of MS
(Table 3).
The most frequent components of MS  deﬁnition were
abdominal adiposity (98.1%), hypertension (80%) and low
HDL (72.2%). Hypertriglyceridemia and glucose intoler-
ance/diabetes mellitus were present in 59.2% and 46.3%,
respectively (Table 4).
Discussion
Although several studies on prevalence of MS  in RA have
already been performed worldwide, the frequency found
varies from 14 to 63% among the various populations
studied, not always the values found are higher than in
controls, and the association of factors related to rheuma-
toid arthritis (disease activity, inﬂammatory markers, severity
of the disease, treatment) with MS varies greatly in the
literature.14–16,18,23–27,29 A frequent explanation for these dis-
crepancies is the use of different criteria for MS  classiﬁcation.
However, even when observing studies that used the same
criteria, the prevalence rates vary widely (Table 5). Therefore, it
is likely that other factors related to the characteristics of the
study population, including genetic, ethnic, cultural, demo-
graphic, socioeconomic and clinical factors, also inﬂuence
the prevalence rates. Thus, studies conducted with different
populations are critical to try to detect other factors more
associated with MS speciﬁc of that population and, from this
point, one could try to interfere on such factors, in addition to
offering information to a better understanding of the patho-
physiological relationship between the different components
and other cardiovascular risk factors.
The majority of the patients seen in this study were female,
with a mean age of 55.5 years, of low socioeconomic status,
with long-standing disease, and moderate disease activity; the
vast majority of subjects in this sample were in chronic use of
low-dose prednisone, were methotrexate and/or leﬂunomide
users, and 1/3 of them was in use of anti-TNF alpha agents.
The prevalence of MS was about 50% when using NCEPIII (2005)
criteria, and of 53.4% with IDF (2006) deﬁnitions. Both deﬁni-
tions require the presence of three out of ﬁve criteria, but the
main difference is that IDF requires obesity (waist circumfer-
ence ≥94 cm for men  or ≥80 cm for women) as one of these
three criteria, and the cutoff point to consider the presence
of obesity is lower than that adopted in the NCEPIII deﬁnition
(≥102 cm for men  and ≥88 cm for women); the other four crite-
ria are the same. For this reason, the MS rate by IDF deﬁnition is
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Table 2 – Characteristics of rheumatoid arthritis patients followed at the Hospital Universitário Walter Cantídio-UFC
according to the presence or absence of metabolic syndrome (NCEP III).
Metabolic syndrome (+) (n = 55) Metabolic syndrome (−) (n = 55) p
Demographics
Female gender (%) 100.0 94.5 0.07
Age, years (mean ± SD) 57.9 ± 11.9 52.9 ± 13.5 0.04
Caucasian/brown race (%) 52.7 56.4 0.82
Educational level ≥ high school (%) 25.5 27.3 0.83
Clinical features
Disease duration, years (mean ± SD) 11.8 ± 7.2 10.5 ± 7.4 0.34
Rheumatoid factor (%) 84.9 83.0 0.79
Extra-articular manifestations (%) 9.0 14.5 0.30
Number of DMARDs (mean ± SD) 2.3 ± 0.8 2.5 ± 0.9 0.53
Current prednisone dose, mg/day (mean ± SD) 5.3 ± 2.1 4.8 ± 2.2 0.33
Methotrexate use (%) 94.5 96.3 0.64
Irreversible deformities (%) 35.2 24.5 0.22
Radiological erosions (%) 37.9 30.7 0.57
HAQ (mean ± SD) 1.07 ± 0.72 0.88 ± 0.65 0.17
DAS 28 (mean ± SD) 3.89 ± 1.38 4.05 ± 1.39 0.64
Cardiovascular risk factors
Smoking history >20 packs/year (%) 29.0  9.0 0.008
Hypertension (%) 80.0 32.7 0.0001
Low HDL (%) 72.2 21.1 0.0001
Triglycerides >150 mg/dL (%) 59.2 16.9 0.0001
Diabetes mellitus/glucose intolerance (%) 46.3 16.7 0.001
Abdominal adiposity (%) 98.1 52.7 0.0001
BMI ≥ 30 kg/m2 (%) 56.3 20 0.0001
Sedentary lifestyle (%) 56.4 50.9 0.56
Menopause (%) 83.3 72.0 0.09
Inﬂammatory markers
CRP (mg/dL) (mean ± SD) 0.95 ± 1.3 0.87 ± 0.85 0.69
ESR (mean ± SD) 28.4 ± 20.5 30.9 ± 22.7 0.54
index
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1DMARDs, disease-modifying antirheumatic drugs; BMI, body mass 
Score; ESR, erythrocyte sedimentation rate.
lmost always a little higher than 2005 NCEPIII’s. With respect
o demographic and clinical factors, only older age was asso-
iated with MS  in this study. We  found no association with
isease duration, use of glucocorticoids, functional capacity
nd disease activity. What drew a lot of attention was the high
revalence of abdominal obesity in patients with MS (98.1%)
nd the association between heavy smoking story and MS.
The prevalence of MS  in our study has been among the
argest ever recorded in all studies (Table 5). Comparing only
tudies using the deﬁnition of NCEPIII, MS prevalence in
A among various international populations ranged from
9% to 55.5%. Also, considering only studies that included a
Table 3 – Exposure to oral corticosteroids (prednisone) in
rheumatoid arthritis patients with metabolic syndrome
(NCEP III) and without metabolic syndrome followed at
the Hospital Universitário Walter Cantídio-UFC.
Corticosteroid dose Patients with
metabolic
syndrome (n/%)
Patients without
metabolic
syndrome (n/%)
Not exposed, or very
low exposure
4  (7.27%) 7 (12.96%)
Low exposure 44 (80%) 42 (77.78%)
Medium exposure 7 (12.73%) 5 (9.26%); HAQ, Health Assessment Questionnaire; DAS28, Disease Activity
control group, some did not ﬁnd a relationship between MS
and RA,14,15,20,24 others have found increased MS,16,22,25,26,28
and two studies showed higher rates in controls than in
patients with RA.21,29 The study by La Montagna et al.,15 con-
ducted at the University of Naples, Italy, with 45 patients
and 48 controls (patients with myofascial pain, carpal tunnel
syndrome and shoulder periarthritis), found a MS  rate in RA
similar to ours (55.5%). La Montagna’s patients had clinical and
demographic characteristics similar to those of our patients
with regard to age, disease duration, gender and current dose
of glucocorticoids. However, they also found a high preva-
lence of MS in controls (45.8%), with no statistical difference
between the two groups. Although our study lacked a control
Table 4 – Metabolic syndrome (NCEP III)
parameterspresent in patients with rheumatoid arthritis
followed at the Hospital Universitário Walter
Cantídio-UFC.
Metabolic syndrome component Percentage (%)
Hypertension 80.0
Abdominal adiposity 98.1
Low HDL 72.2
High triglycerides 59.2
Fasting glycaemia ≥100 mg/dL and/or DM 46.3
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Table 5 – Prevalence of metabolic syndrome in patients with rheumatoid arthritis according to several studies.
Author, year Study design Number of
patients with
RA/controls
Age, years
(mean ± SD or
median, IQR)
Disease
duration, years
(mean ± SD or
median, IQR)
Prevalence of
metabolic
syndrome in
RA (%)
Deissein et al., 2006 Cross-sectional 74 55.8 (53.2–58.3) 12.8 (12.3–15.2) 19% (NCEPIII
2005)
14% (WHO)
Karvounaris et al., 2007 Case–control 200/400 63 ± 11 9.3 ± 8.8 44% (NCEPIII
2001)
La Montagna et al., 2007 Case–control 45/48 53.8 ± 11.6 12.6 ± 8.2 55.5% (NCEPIII
2005)
Chung et al., 2008 Case–control 154/85 59 (52–67) 20 (14–24) 42% (NCEPIII
2001)
42% (WHO)
Zonana-Nacach et al., 2008 Cross-sectional 107 48 ± 12 11.2 ± 9.3 18.7% (NCEPIII
2001)
Toms et al., 2009 Cross-sectional 400 63.0 (55.4–69.2) 10 (4–18) 40.1% (NCEPIII
2005)
45.3% (IDF)
19.4% (WHO)
Elkan et al., 2009 Cross-sectional 80 61.4 ± 12 6 (2–15) 20% (women)
(IDF)
63% (men) (IDF)
Giles et al., 2010 Case–control 131/121 61 ± 9 9 (5–17) 36% (NCEPIII
2005)
Sahebari et al., 2011 Case–control 120/500 45.5 ± 13 5.5  ± 5.2 30.8% (IDF)
45.2% (NCEPIII
2001)
Crowson et al., 2011 Case–control 232/1241 58.8 ± 12.8 7 (4.1–12.8) 33% (NCEPIII
2005)
Mok et al., 2011 Cross-sectional 699 53.3 ± 12 5.3 ± 5.4 20% (NCEPIII
2005)
Karimi et al., 2011 Case–control 92/96 48.3 ± 14.6 8 (5–14) 27.2% (NCEPIII
2001)
19.6% (WHO)
Da Cunha et al., 2012 Case–control 283/226 56.8 ± 12.3 11.1 (4.9–16) 39% (NCEPIII
2005)
Karakoc et al., 2012 Case–control 54/52 49.7 ± 11.1 7.6 42.6% (NCEPIII
2005)
Lee et al., 2013 Case–control 84/109 50.6 ± 11.3 3.5 (2.0–6.3) 19% (NCEPIII
2005)
Rostom et al., 2013 Case–control 120/100 49 ± 12 7.8 32.4% (NCEPIII
2005)
48.6% (IDF)
20% (WHO)
Salinas et al., 2013 Case–control 409/624 55.5 ± 13.2 8 (4–15) 30% (NCEPIII
2005)
35% (IDF)
Medeiros et al., 2014a Cross-sectional 110 57.9 ± 11.9 11.8 ± 7.2 50% (NCEPIII
2005)
53.4% (IDF)IQR, interquartile range.
a Current study.
group, a systematic review recently published (2013) on the
prevalence of MS  in the Brazilian adult population included
10 studies conducted in several Brazilian regions, showing a
mean rate of 29.6% for MS.37 The only study conducted in
Northeastern Brazil was in a random population-based sam-
ple that consisted of 240 subjects aged 25–87 years in a town
of the semi-arid region of Bahia, where an age-adjusted rate
of 24.8% was found with the use of NCEPIII 2001 deﬁnitions
(cutoff point for glucose >110 mg/dL, rather than 100 mg/dLby NCEPIII 2005). La Montagna et al.15 found a higher preva-
lence of IR (88.9% versus 6.2%) and a higher number of cases of
subclinical atherosclerosis (assessed by measuring common
carotid artery intima and media thicknesses by ultrasound)
in patients with RA. The study by Karvounaris et al.,14 held
in Greece with 200 patients with RA and a control group
of subjects without RA or other chronic inﬂammatory dis-
eases, found a MS rate (NCEPIII 2001) of 44% in RA patients
and of 41% in controls, also without signiﬁcant difference. An
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nteresting fact was observed in this study: a much higher pro-
ortion of controls with abdominal obesity (83% of controls
ersus 71% of patients) and hypertension (77.5% of controls
ersus 66% of patients) – features which may be related to
ietary habits of this population. Glucocorticoids were used
y less than 30% of patients and anti-TNF-alpha agents by
bout 40%. The little use of glucocorticoids and the consider-
ble rate of biological users may have contributed to ﬂatten the
S rate among patients, narrowing the gap between patient
nd control groups. Favorable effect of anti-TNF-alpha agents
n IR in patients with RA has been documented.38,39 With
egard to corticosteroids, both cumulative dose and chronic
orticosteroid use were associated with IR and subclinical
therosclerosis in the Italian study, and its authors believe that
xposure to glucocorticoids may be the triggering factor for
R and atherosclerosis. In our study, we  found no association
etween exposure to oral glucocorticoids and MS, but IR and
ubclinical atherosclerosis are earlier alterations than MS;  fur-
hermore, over 90% of our sample of patients with RA was in
ontinued use of low-dose prednisone, making it difﬁcult the
emonstration of a statistically signiﬁcant difference between
roups, if in fact this difference occurred. Other studies also
howed that the continuous use of corticosteroids is an inde-
endent predictor of IR and MS  in patients with RA,13,28 while
ther authors have found no such association.18 It seems
hat, thanks to their systemic anti-inﬂammatory effect, short-
erm glucocorticoids could improve IR,40,41 but the long-term
ide effects (dyslipidemia, hyperglycemia, hypertension, IR
nd abdominal obesity) could collectively contribute to an
ncrease of insulin resistance and the development of MS and
therosclerosis.
An American study with 131 patients and 121 controls
ithout RA showed MS  rates of 36% in RA and 27% in controls,
ith no statistically signiﬁcant difference.20 Although BMI  and
aist circumference values were similar between groups, the
uantiﬁcation of visceral fat by abdominal CT was higher in
ale patients than in male controls, while subcutaneous fat
as  higher in female patients than in female controls. Fur-
hermore, the authors found a more  important association of
isceral fat with cardiometabolic risk factors in patients with
A of both genders versus controls, even in the face of simi-
ar waist circumference values. This has important practical
mplications, because measures to reduce visceral fat (weight
oss) appear to exert most impact in reducing cardiovascular
isk in patients with RA than in the general population. In
ur study, the most frequent component of MS  was abdom-
nal obesity, found in almost all patients (98.1%); and BMI
30 kg/m2, indicating body obesity, was also found in more
han half of our patients with MS. These two ﬁndings char-
cterize a population of overweight patients, that may be
econdary to carbohydrate-based eating habits, characteris-
ic of the Northeastern Brazil population, sedentary lifestyle
more than half of patients), and chronic use of glucocorticoids
90.9%). Nutritional guidance, an adequate physical activity
rogram and a more  rational use of glucocorticoids can con-
ribute to decrease the cardiovascular risk in patients with
A.
Another study that did not ﬁnd an increased prevalence of
S in RA was held in Iran with 92 female RA patients, and
6 healthy women, with rates of 27.2% in patients and 35.4% 6;5 6(2):117–125 123
in controls.24 The mean age of patients (48.3 ± 14.6 years) and
the duration of illness (median: 8 years) were lower than our
ﬁndings. An interesting ﬁnding of this study is that over 90%
of patients were taking hydroxychloroquine. A multicenter
study in Argentina published quite recently (2013) evaluated
409 patients with RA and 624 controls and found a protec-
tive effect of hydroxychloroquine in MS.29 In the Argentinian
study the control group consisted of patients without RA and
diagnosed with other rheumatic diseases: osteoarthritis, low
back pain, ﬁbromyalgia. The prevalence of MS  by NCEPIII (2005)
criteria was of 30% and 39% for patients and controls, respec-
tively, with no statistically signiﬁcant difference. Perhaps the
patient characteristics in the control group caused an increase
in the MS rate for this group, narrowing the gap between
this group and RA patients’ group. The only other factors
associated with MS in this study were age and rheumatoid
factor and anti-CCP positivity. Lee et al.27 from Korea reported
the lowest prevalence of MS in both AR and control groups
(19% and 15.6%), with 84 cases and 109 healthy controls, all
female. These patients presented an earlier disease (median:
3.5 years) and were younger (50.6 ± 11.3 years). In addition
to these demographic factors, genetic and cultural charac-
teristics and factors related to dietary habits speciﬁc of this
population may have contributed to such low MS  rate. In the
Korean study, RA patients had abdominal obesity (29.8%) and
hypertension (44%) rates lower than in our study.
The ﬁrst study showing an increase of MS  in RA was con-
ducted at the University of Tennessee, USA, and published
in 2008 with 154 patients and 85 controls (without chronic
inﬂammatory disease).16 Using NCEPIII 2001 deﬁnition, 42%
of patients with long-standing RA (median: 20 years), 30% of
patients with early RA (median: 2 years) and 22% of controls
had MS. Compared to the present study, a higher propor-
tion of male patients was included in the Tennessee study
(27% versus 2.7%), the subjects had a higher level of educa-
tion, and there had more  Caucasian patients (∼90% versus
22.4%). These factors may explain, in part, an MS  rate slightly
lower than that found in our study. Also in that study, the
authors demonstrated a protective effect of hydroxychloro-
quine. In 2011, another American study by Crowson et al.22
was published. This study recruited 232 cases and 1241 con-
trols (patients without RA), showing 33% and 25% for MS,
respectively. The authors believe that the exclusion of patients
with previous cardiovascular disease may have decreased the
actual prevalence of MS in their patients. Two other studies in
Turkey26 and Morocco28 showed prevalence rates of 42.6% and
32.4%, respectively, with statistically signiﬁcant differences
compared to controls. In both studies, patients were younger
and had less-lengthy disease, compared to our patients. High
ESR and glucocorticoid use were associated with MS  in the
Moroccan study.
A Brazilian study by Cunha et al. conducted in the city of
Porto Alegre and recently published (2012) included 283 RA
patients and 226 healthy controls. In this study a higher rate of
MS in patients versus controls (39% versus 19.5%) was found.25
The means of age and disease duration were similar to those
in our study, but the proportion of male patients was higher
in Cunha’s study (17.7% versus 2.7%). Cases and controls
exhibited similar prevalence of obesity. In patients with RA,
MS was associated with older age, lower educational level,
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disease activity and a worst HAQ score. Older age has been
associated with presence of MS  in several studies, as well as in
our study. A likely explanation for this is the increased chance
of developing factors related to MS  with the progression of
age. Disease duration, presence of rheumatoid factor, extra-
articular manifestations, smoking history ≥20 packs/year,
use of glucocorticoids, antimalarials or methotrexate and
inﬂammatory markers were not associated with MS  in the
study by Cunha et al.25 An association between inﬂammatory
activity and MS  has been found by some authors,14,16,23,27
but not by others.21,24,26,29 Inﬂammatory cytokines present
in RA, especially TNF-alpha and IL-6, increase IR, which
promotes hyperglycemia, compensatory hyperinsulinemia
and dyslipidemia,23 favoring a higher risk for developing MS.
The controversial association between inﬂammatory activity
of RA and MS  can be explained by the instruments used in
studies to assess inﬂammation. Both the Disease Activity
Score (DAS28) and serological inﬂammatory markers (ESR,
CRP) evaluate time-point activity, not activity over time.
Cross-sectional studies have shown MS  prevalence in RA
ranging from 17% to 40.1% by NCEPIII criteria.13,17–19,23 A UK
study by Toms et al.18 examined the relationship of expo-
sure to glucocorticoids with MS, categorizing the exposure in
“no exposure”, “low exposure” (<7.5 mg/day for >6 months), or
“medium exposure” (7.5–30 mg/day for >6 months), similar to
our study. Neither the authors’ nor the present study found
any association of corticosteroid use with MS. In the Mexi-
can study by Zonana-Nacach et al.17 evaluating MS in patients
with RA and systemic lupus erythematous, the frequency of
MS was 18.7% and 16.7%, respectively. The variables associated
with MS  were older age, educational level, monthly income
and smoking. In our study, we found an association between
smoking history >20 packs/year and MS. The association
between smoking and MS  is not fully understood. Although
there are several studies showing an association, especially
in males,42 the presence of other factors related to smokers’
lifestyle could explain this association. For example, sedentary
lifestyle and alcoholism are admittedly more  common among
smokers and could act as confounding variables.43
This study has some limitations. The lack of a control group
without RA precludes a comparison of MS  prevalence among
RA patients and individuals without the disease in this popu-
lation. Thus, while a prevalence of 50% in patients may seem
high, one cannot say that MS  occurs more  often in RA patients
than in people without RA. MS  prevalence studies in an adult
Brazilian population by other authors37 make us believe that
the rate found in the present study has been larger than in
the general population (29.6%). However, genetic, cultural and
nutritional characteristics speciﬁc of Brazilian regions should
be considered, and perhaps the Brazilian rate is not a good
reference of control for a Northeastern population. Another
limitation of the study was related to sample size, which may
have inﬂuenced the lack of statistical signiﬁcance of some
comparisons.
In summary, patients with a diagnosis of RA followed in a
tertiary center of a university hospital in Northeastern Brazil
present one of the highest prevalence rates of MS, when com-
pared to studies in various parts of the world, including Brazil.
Regarding the components of MS, it should be noticed the
high proportion of patients with abdominal adiposity (98.1%),
1 0 1 6;5 6(2):117–125
hypertension (80%) and low HDL (72.2%). Greater attention
should be given to these patients regarding nutritional guid-
ance and physical activity, in order to promote weight loss and
a better control of metabolic changes. Heavy smoking was also
signiﬁcantly associated with MS in this study, but one cannot
say that smoking is a risk factor for MS.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M,  Esdaile
JM, Lacaille D. Risk of cardiovascular mortality in patients
with rheumatoid arthritis: a meta-analysis of observational
studies. Arthritis Rheum. 2008;59:1690–7.
2. Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J,
Hørslev-Petersen K, Luukkainen RK, et al. Cardiovascular
disease in patients with rheumatoid arthritis: results from
the QUEST-RA study. Arthritis Res Ther. 2008;10:R30.
3. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK,
et  al. Metabolic syndrome and risk of incident cardiovascular
events and death: a systematic review and meta-analysis of
longitudinal studies. J Am Coll Cardiol. 2007;49:403–14.
4. Reaven G. The metabolic syndrome or the insulin resistance
syndrome? Different names, different concepts, and
differents goals. Endocrinol Metab Clin N Am.
2004;33:283–303.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.
Lancet. 2005;365:1415–28.
6. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al.
The metabolic syndrome and cardiovascular risk: a
systematic review and meta-analysis. J Am Coll Cardiol.
2010;56:1113–32.
7. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H,
Fujii  K, et al. The metabolic syndrome as a predictor of
nonalcoholic fatty liver disease. Ann Intern Med.
2005;143:722–70.
8. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and
characteristics of the metabolic syndrome in women with
polycystic ovary syndrome. J Clin Endocrinol Metab.
2005;90:1929–35.
9. Grundy SM. Cholesterol gallstones: a fellow traveler with
metabolic syndrome. Am J Clin Nutr. 2004;80:1–2.
0. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding
JP. Obstructive sleep apnoea is independently associated with
na increased prevalence of metabolic syndrome. Eur Heart J.
2004;25:735–41.
1. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca
V,  et al. The metabolic syndrome and chronic kidney disease
in  US adults. Ann Intern Med. 2004;140:167–74.
2. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic
syndrome in patients with gout: the Third National Health
and  Nutrition Examination Survey. Arthritis Care Res.
2007;57:109–15.
3. Deissein PH, Tobias M, Veller MG. Metabolic syndrome and
subclinical atherosclerosis in rheumatoid arthritis. J
Rheumatol. 2006;33:2425–32.4. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK,
Bertsias GK, Kritikos HD, et al. Metabolic syndrome is
common among middle-to-older aged Mediterranean
patients with rheumatoid arthritis and correlates with
 . 2 0 1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4r e v b r a s r e u m a t o l
disease activity: a retrospective, cross-sectional, controlled,
study. Ann Rheum Dis. 2007;66:28–33.
5. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo
GA, Arciello A, et al. Insulin resistance is an independent risk
factor for atherosclerosis in rheumatoid arthritis. Diabetes
Vasc Dis Res. 2007;4:130–5.
6. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani
A,  et al. Prevalence of the metabolic syndrome is increased in
rheumatoid arthritis and is associated with coronary
atherosclerosis. Atherosclerosis. 2008;196:756–63.
7. Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ,
Camargo-Coronel A. Prevalence and factors associated with
metabolic syndrome in patients with rheumatoid arthritis
and systemic lupus erythematosus. J Clin Rheumatol.
2008;14:74–7.
8. Toms TE, Panoulas VF, Douglas KMJ, Grifﬁths HR, Kitas GD.
Lack of association between glucocorticoid use and presence
of  the metabolic syndrome in patients with rheumatoid
arthritis: a cross-sectional study. Arthritis Res Ther.
2008;10:R145.
9. Elkan AC, Hakansson N, Frostegard J, Cederholm T, Hafstrom
I. Rheumatoid cachexia is associated with dyslipidemia and
low  levels of atheroprotective natural antibodies against
phosphorylcholine but not with dietary fat in patients with
rheumatoid arthritis: a cross-sectional study. Arthritis Res
Ther. 2009;11:R37.
0. Giles JT, Allison M, Blumenthal RS, Post W,  Gelber AC, Petri M,
et  al. Abdominal adiposity in rheumatoid arthritis.
Association with cardiometabolic risk factors and disease
characteristics. Arthritis Rheum. 2010;62:3173–82.
1. Sahebari M, Goshayeshi L, Mirfeizi Z, Rezaieyazdi Z, Hatef MR,
Ghayour-Mobarhan M, et al. Investigation of the association
between metabolic syndrome and disease activity in
rheumatoid arthritis. Sci World J. 2011;11:1195–205.
2. Crowson CS, Myasoedova E, Davis JM, Matteson EL, Roger VL,
Therneau TM, et al. Increased prevalence of metabolic
syndrome associated with rheumatoid arthritis in patients
without clinical cardiovascular disease. J Rheumatol.
2011;38:29–35.
3. Mok CC, Ko GTC, Ho LY, Yu KL, Chan PT, To CH. Prevalence of
atherosclerotic risk factors and the metabolic syndrome in
patients with chronic inﬂammatory arthritis. Arthritis Care
Res.  2011;63:195–202.
4. Karimi M, Mazloomzadeh S, Kafan S, Amirmoghadami H. The
frequency of metabolic syndrome in women with rheumatoid
arthritis and in controls. Int J Rheum Dis. 2011;14:
248–54.
5. da Cunha VR, Brenol CV, Brenol JCT, Fuchs SC, Arlindo EM,
Melo IMF, et al. Metabolic syndrome prevalence is increased
in  rheumatoid arthritis patients and is associated with
disease activity. Scand J Rheumatol. 2012;41:186–91.
6. Karakoc M, Batmaz I, Sariyildiz MA, Tahtasiz M, Cevik R,
Tekbas E, et al. The relationship of metabolic syndrome with
disease activity and the functional status in patients with
rheumatoid arthritis. J Clin Med Res. 2012;4:279–85.
7. Lee SG, Kim JM, Lee SH, Kim KH, Kim JH, Yi JW,  et al. Is the
frequency of metabolic syndrome higher in South Korean
women with rheumatoid arthritis than in healthy subjects.
Korean J Intern Med. 2013;28:206–15.
8. Rostom S, Mengat M, Lahlou R, Hari A, Bahiri R,
Hajjaj-Hassouni N. Metabolic syndrome in rheumatoid
4 6;5 6(2):117–125 125
arthritis: case control study. BMC Musculoskelet Disord.
2013;14:147.
9. Salinas MJH, Bertoli AM, Lema L, Saucedo C, Rosa J, Quintana
R,  et al. Prevalence and correlates of metabolic syndrome in
patients with rheumatoid arthritis in Argentina. J Clin
Rheumatol. 2013;19:439–43.
0. Pereira IA, Henrique da Mota LM, Cruz BA, Brenol CV, Fronza
LSR, Bertolo MB, et al. Consenso 2012 da Sociedade Brasileira
de  Reumatologia sobre o manejo de comorbidades em
pacientes com artrite reumatoide. Rev Bras Reumatol.
2012;52:474–95.
1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association
1987 revised criteria for the classiﬁcation of rheumatoid
arthritis. Arthritis Rheum. 1988;31:315–24.
2. Frare e Silva RL, Carmes ER, Scwartz AF, Blaszkowski DS,
Cirino RHD, Ducci RDP. Cessac¸ão de tabagismo em pacientes
de  um hospital universitário em Curitiba. J Bras Pneumol.
2011;37:480–7.
3. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA,  van de
Putte LB, van Riel PL. Modiﬁed disease activity scores that
include twenty-eight-joint counts. Development and
validation in a prospective longitudinal study of patients with
rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
4. Ferraz MB, Oliveira LM, Araujo PM, Atra E, Tugwell P.
Crosscultural reability of the physical ability dimension of the
Health Assessment Questionnaire. J Rheumatol.
1990;17:813–7.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH,
Franklin BA, et al. Diagnosis and management of the
metabolic syndrome. An American Heart
Association/National Heart, Lung, and Blood Institute
Scientiﬁc statement. Circulation. 2005;112:2735–52.
6. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new
worldwide deﬁnition. A consensus statement from the
International Diabetes Federation. Diabet Med.
2006;23:469–80.
7. Vidigal FC, Bressan J, Babio N, Salas-Savado J. Prevalence of
metabolic syndrome in Brazilian adults: a systematic review.
BMC Public Health. 2013;13:1198.
8. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D,
Raptopoulou A, et al. Anti-tumor necrosis factor therapy
improves insulin resistance, beta cell function and insulin
signaling in active rheumatoid arthritis patients with high
insulin resistance. Arthritis Res Ther. 2012;14:R141.
9. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez
TR, Miranda-Filloy JA, Llorca J. Insulin resistance in
rheumatoid arthritis: the impact of the anti-TNF-alpha
therapy. Ann N Y Acad Sci. 2010;1193:153–9.
0. Svenson KLG, Pollare T, Lithell H, Hallgren R. Impaired
glucose handling in active rheumatoid arthritis: relationship
to peripheral insulin resistance. Metabolism. 1998;37:125–30.
1. Deissen PH, Joffe BJ, Stanwix AE, Christian BF, Veller M.
Glucocorticoids and insulin sensitivity in rheumatoid
arthritis. J Rheumatol. 2004;131:867–74.
2. Sun K, Liu J, Ning G. Active smoking and risk of metabolic
syndrome: a meta-analysis of prospective studies. PLoS ONE.
2012;7:e47791.
3. Rabaeus M, Salen P, de Lorgeril M. Is it smoking or related
lifestyle variables that increase metabolic syndrome risk?
BMC Med. 2013;11:196.
